On the Record · Tandem Diabetes Care
Tandem Diabetes Care competitors, on the record
The companies Tandem Diabetes Care names as competitors in its annual reports, 2023 to 2025, and the companies that name Tandem Diabetes Care, each with the sentence and the filing.
Who Tandem Diabetes Care names
| Company | Named in |
|---|---|
| Beta Bionics | 2025 |
| Insulet | 2025 |
| Medtronic | 2025 |
| mylife (formerly Ypsomed) | 2025 |
| Sequel | 2025 |
In its own words
Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed), Sequel
Word for word“Our primary competitors are major medical device companies, primarily Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed) and Sequel.” 10-K for 2025
Who names Tandem Diabetes Care
Companies whose own annual reports name Tandem Diabetes Care as a competitor.
Word for word“We compete with established companies that produce insulin pumps, such as Medtronic Diabetes, a division of Medtronic plc (which division is being spun out into a new, independent publicly traded company), Tandem Diabetes Care Inc., as well as emerging companies like Beta Bionics Inc.” 10-K for 2025
Word for word“We compete with companies such as Beta Bionics, Inc.; Dexcom, Inc.; Insulet Corporation; Sequel Med Tech, LLC; and Tandem Diabetes Care, Inc.” 10-K for 2026
Read from Tandem Diabetes Care’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.